Overview

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended-release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Sandoz
Treatments:
Oxymorphone
Criteria
Inclusion Criteria:

- No clinically significant abnormal findings on physical exam, medical history or
clinical laboratory results on screening.

Exclusion Criteria:

- Positive test results for HIV or hepatitis B or C

- Treatment for drug or alcohol dependence